Stay updated with breaking news from Multimodality Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in progression-free
In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstra
Share this article Share this article NEW BRUNSWICK, N.J., May 19, 2021 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and health outcomes analyses and a designated Comprehensive Cancer Center by the National Cancer Institute, together with RWJBarnabas Health, today announced that data from its cancer clinical research program will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held virtually from June 4-8. A total of 16 presentations including 13 abstracts, two educational sessions and one clinical...